At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 88 enrolled
Drug / intervention
IW-1701 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease
In Brief
A Phase 2 clinical trial evaluating IW-1701 and Placebo for Sickle Cell Disease. Completed, enrolled 88 participants across 37 sites in 3 countries.
Detailed Summary
The primary objective of the 1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW-1701 compared with placebo when administered daily for approximately 12 weeks to patients with stable SCD. Exploratory objectives include evaluation of pharmacokinetic (PK) as well as evaluation of the effect of IW-1701 on symptoms of SCD, health-related quality of life, and biomarkers of pharmacodynamic (PD) activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesLebanon, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartDec 2017
Primary CompletionJul 2020
TodayJul 2026
First PostedSep 15, 2017
Enrollment StartDec 22, 2017
Primary CompletionJul 22, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.8 years ago
Interventions
IW-1701drug
Oral Tablet
Placebodrug
Oral Tablet